Document Detail

Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study.
MedLine Citation:
PMID:  21067858     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To find the optimal dosage of estradiol (E2) for luteal phase support through the addition of different doses of E2 to progeserone (P) luteal phase support in patients undergoing long GnRH agonist in vitro fertilization (IVF) treatments.
STUDY DESIGN: Two hundred and eighty-five women undergoing IVF treatment with a long GnRH agonist protocol were prospectively randomized into three groups. Group 1 (n = 95) received P and 2mg E2, group 2 (n = 95) received P and 4 mg E2 and group 3 (n = 95) received P and 6 mg E2 as luteal phase support. The primary outcome was the clinical pregnancy rate (PR). The secondary variables of interest were the implantation rate (IR), miscarriage rate and multiple PR.
RESULTS: The clinical PR was 31.6%, 40% and 32% respectively in groups 1, 2 and 3 and the differences between groups were not statistically significant. However, the miscarriage rate was significantly lower in group 2 (2.6%) than in group 1 (20%) but was not significantly lower than in group 3 (9.6%).
CONCLUSION: For luteal phase support, adding 2, 4 or 6 mg of oral E2 to P creates no statistical difference in terms of pregnancy rates. However, a significantly higher miscarriage rate was found when 2mg E2 was used. Therefore, in the luteal phase support, 4 mg of oral estradiol in addition to progesterone can be considered to reduce the miscarriage rate.
CONDENSATION: For luteal phase support, adding 2, 4 or 6 mg of oral estradiol to progesterone showed no statistical difference in terms of pregnancy and implantation rates, but a significantly higher miscarriage rate was found when 2mg estradiol was used.
Esra Tonguc; Turgut Var; Sebnem Ozyer; Ayse Citil; Muammer Dogan
Related Documents :
19573818 - Laparoscopy vs minilaparotomy in women with symptomatic uterine myomas: a prospective r...
2883138 - Results of human menopausal gonadotropin therapy at the boston hospital for women (1979...
11957148 - Relationship between platelet-derived growth factor expression in leiomyomas and uterin...
1740208 - Performance of cryopreserved pre-embryos obtained in in vitro fertilization cycles with...
9344188 - Combined topical calcipotriene ointment 0.005% and various systemic therapies in the tr...
18038208 - A modified percutaneous transhepatic variceal embolization with 2-octyl cyanoacrylate v...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-11-09
Journal Detail:
Title:  European journal of obstetrics, gynecology, and reproductive biology     Volume:  154     ISSN:  1872-7654     ISO Abbreviation:  Eur. J. Obstet. Gynecol. Reprod. Biol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-14     Completed Date:  2011-06-01     Revised Date:  2011-08-25    
Medline Journal Info:
Nlm Unique ID:  0375672     Medline TA:  Eur J Obstet Gynecol Reprod Biol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  172-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortion, Spontaneous / chemically induced
Estradiol / administration & dosage*,  adverse effects
Fertilization in Vitro / methods
Luteal Phase / drug effects*
Ovulation Induction / methods*
Pregnancy Rate
Progesterone / administration & dosage
Reg. No./Substance:
50-28-2/Estradiol; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prospective evaluation of tools to assess the psychological response of CPR provision to a relative ...
Next Document:  Heavy metal removal from industrial effluents by sorption on cross-linked starch: chemical study and...